Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

News Conference News CRT 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

March 10, 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

News Conference News STS 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

Yael L. Maxwell

January 27, 2025

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

News Conference News TCT 2024

After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry

Yael L. Maxwell

November 05, 2024

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

News Conference News TCT 2024

More Registry Data Show Post-TAVI Benefits With Sentinel but No Stroke Impact

Yael L. Maxwell

October 28, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Rogers.1-CRT2021.jpg

News Conference News CRT 2021

LRT Trial Data Bolster Support for TAVI in Bicuspid Valves

March 11, 2021

DOAC Use Increasing in Patients With Bioprosthetic Heart Valves

News Conference News CRT 2021

DOAC Use Increasing in Patients With Bioprosthetic Heart Valves

March 08, 2021

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

News Conference News TCT 2020

Valve Disease Plus COVID-19 Often a Lethal Combination, Registry Shows

October 14, 2020

Stroke in TAVR Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

News Conference News TVT 2020

Stroke in TAVR: Full Impact of Embolic Devices, Anticoagulants, Technique Remain Unclear

June 25, 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

April 07, 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

February 24, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.